New study aims to personalize kaposi sarcoma treatment in africa
NCT ID NCT06480773
First seen Feb 05, 2026 · Last updated Jun 15, 2026 · Updated 25 times
Summary
This study is observing 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa to understand why some respond better to standard chemotherapy than others. Participants receive either paclitaxel or a bleomycin/vincristine combination, based on local guidelines. The goal is to identify factors that predict treatment success, so doctors can tailor therapies more effectively in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stellenbosch University and Tygerberg Hospital
Cape Town, Stellenbosch, 8000, South Africa
-
UNC Project, Kamuzu Central Hospital
Lilongwe, Malawi
Conditions
Explore the condition pages connected to this study.